Please login to the form below

Not currently logged in
Email:
Password:

New flu shots approved

The US Food and Drug Administration has approved vaccines for the 2010-2011 flu season covering three strains of flu, including the H1N1 virus

The US Food and Drug Administration (FDA) has approved vaccines for the 2010-2011 flu season. The vaccines all protect against three strains of flu, including the H1N1 virus.

"Last year because the 2009 H1N1 virus emerged after production began on the seasonal vaccine, two separate vaccines were needed to protect against seasonal flu and the 2009 H1N1 pandemic flu virus, but this year, only one vaccine is necessary," the FDA noted.

The approved vaccines for the upcoming season are CSL's Afluria; Novartis' Agriflu and Fluvirin; GlaxoSmithKline's (GSK) Fluarix; ID Biomedical's FluLaval; MedImmune's FluMist; and Sanofi Pasteur's Fluzone and Fluzone High-Dose.

The FDA noted that the labelling of CSL's Afluria has been updated to warn of an increased incidence of fever and febrile seizures in young children. The warning is based on adverse event reports collected after administration of the 2010 Southern Hemisphere formulation of the vaccine. As a result of the reports, CSL will not be supplying the government with the dosage form of the vaccine designed for use in very young children this year. In addition, the FDA is requiring the company to conduct a new paediatric study of the vaccine.

The upcoming flu season will be the first since the US Centers for Disease Control and Prevention (CDC) expanded its recommendation for annual influenza vaccination to include children as young as six months of age. The CDC also is recommending that healthcare providers begin offering flu vaccines as soon as the shots become available.

Sanofi Pasteur said it had begun shipments of Fluzone immediately following the recent approvals, with initial shipments directed primarily to the CDC for use in the federal Vaccines for Children Program. In all, the company expects to deliver 70 million doses of seasonal influenza vaccine to US healthcare providers this season. 

GSK said that distribution of the first lots of FluLaval, its vaccine for adults, had begun, with distribution of Fluarix, which can be used in patients aged three years and older, to follow in the next several weeks.

3rd August 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics